Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
Running, not enrolling · Phase 2 · Has a placebo group
Conditions studied: Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
In brief
Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms. This trial will study the safety and efficacy of Ensitrelvir (S-217622), an antiviral, to treat individuals with Long COVID in an adult population.
Key facts
- Study ID
- NCT06161688
- Run by
- Timothy Henrich
- People needed
- 40
- Starts
- 2024-04-09
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-04-02
Who can join
Age: 18 and older, up to 69. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF/Zuckerberg San Francisco General Hospital — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.